Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $41.00.

ELVN has been the topic of several analyst reports. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st.

Enliven Therapeutics Trading Up 3.4%

ELVN opened at $29.28 on Friday. The stock’s 50 day simple moving average is $23.54 and its 200-day simple moving average is $21.38. The stock has a market cap of $1.74 billion, a PE ratio of -15.91 and a beta of 0.34. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $30.22.

Insider Buying and Selling

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 91,198 shares of Enliven Therapeutics stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the completion of the transaction, the insider directly owned 765,188 shares of the company’s stock, valued at approximately $20,828,417.36. This trade represents a 10.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Anish Patel sold 48,300 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the sale, the chief operating officer owned 215,011 shares in the company, valued at $6,018,157.89. This represents a 18.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 233,843 shares of company stock worth $6,145,489 in the last 90 days. 25.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC acquired a new stake in shares of Enliven Therapeutics in the second quarter valued at $8,024,000. Candriam S.C.A. increased its position in Enliven Therapeutics by 46.3% in the 3rd quarter. Candriam S.C.A. now owns 609,352 shares of the company’s stock valued at $12,473,000 after acquiring an additional 192,702 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Enliven Therapeutics by 7.8% in the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock worth $17,711,000 after acquiring an additional 63,580 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after acquiring an additional 410,034 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Enliven Therapeutics by 177.4% during the second quarter. SG Americas Securities LLC now owns 36,373 shares of the company’s stock worth $730,000 after purchasing an additional 23,261 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.